• Dogwood Therapeutics posted a Q1 net loss of $5 million, narrowing from a $10.9 million loss a year earlier.
• Operating expenses rose 14.6% to $5.08 million, led by R&D up 9.6% to $2.67 million.
• Cash totaled $13.2 million at March 31, 2026, with management expecting it to fund operations into Q4 2026.
• Halneuron Phase 2b HAL-CINP-203 trial enrollment reached 164 patients, with top-line data expected in fall 2026.
• SP16 IND for IV dosing was accepted by FDA, with patient recruitment for an NCI-funded Phase 1 evaluation expected to start in first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-061938), on May 15, 2026, and is solely responsible for the information contained therein.